We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Pmv Pharmaceuticals Inc
1 own
4 watching
Current Price
$1.71
$0.02
(1.18%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
300.93M
52-Week High
9.72000
52-Week Low
1.17500
Average Volume
0.31M
Dividend Yield
--
P/E Ratio
--
Market Capitalization300.93M52-Week High9.7200052-Week Low1.17500Average Volume0.31MDividend Yield--P/E Ratio--What does the Pmv Pharmaceuticals Inc do?
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company s lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Read More
How much money does Pmv Pharmaceuticals Inc make?
News & Events about Pmv Pharmaceuticals Inc.
Globe Newswire
1 year ago
Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next clinical update in 2H 2023Enrolled first patient in combination arm of the ...
Globe Newswire
1 year ago
CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; PMV Pharma), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief ...
Globe Newswire
1 year ago
Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination trial with Merck evaluating PC14586 with KEYTRUDA (pembrolizumab) on track to initiate in...
Globe Newswire
1 year ago
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc.(Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to its Board of ...
Globe Newswire
1 year ago
Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting (ASCO) demonstrated responses in patients across multiple solid tumor types with a p53 Y220C mutationEntered into a clinical collaboration with Merck to evaluate PC14586 in combination with KEYTRUDA; ...
Frequently Asked Questions
Frequently Asked Questions
What is Pmv Pharmaceuticals Inc share price today?
Can Indians buy Pmv Pharmaceuticals Inc shares?
How can I buy Pmv Pharmaceuticals Inc shares from India?
Can Fractional shares of Pmv Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Pmv Pharmaceuticals Inc stocks?
What is today’s traded volume of Pmv Pharmaceuticals Inc?
What is today’s market capitalisation of Pmv Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Pmv Pharmaceuticals Inc?
What percentage is Pmv Pharmaceuticals Inc down from its 52-Week High?
What percentage is Pmv Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$1.71
$0.02
(1.18%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.